Ozempic, a medication used to manage type 2 diabetes, has been found to have an appetite-suppressing effect, which can aid in weight loss [1]. The active ingredient in Ozempic is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist [1].
GLP-1 is a hormone that is released into the bloodstream after eating, which stimulates the pancreas to produce insulin and helps regulate blood sugar levels [2]. Additionally, GLP-1 has been shown to reduce appetite and promote feelings of fullness, leading to a decrease in food intake [3].
Clinical trials have demonstrated that Ozempic can lead to significant weight loss in patients with type 2 diabetes [4]. A study published in the New England Journal of Medicine found that patients taking Ozempic lost an average of 12.4 pounds (5.6 kg) over a 26-week period, compared to 3.2 pounds (1.4 kg) in the placebo group [5].
It is important to note that Ozempic is not approved for weight loss alone, but rather for the treatment of type 2 diabetes. However, the appetite-suppressing effect of the drug can be a beneficial side effect for those looking to manage their weight [1].
In summary, Ozempic is involved in appetite control through its active ingredient, semaglutide, which is a GLP-1 receptor agonist. GLP-1 is a hormone that regulates blood sugar levels and reduces appetite, leading to a decrease in food intake. Clinical trials have shown that Ozempic can lead to significant weight loss in patients with type 2 diabetes.
Sources:
[1] DrugPatentWatch.com. (2022). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (2016). The Role of GLP-1 in Type 2 Diabetes. Retrieved from <https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/glp-1>
[3] Drugs.com. (2022). Ozempic. Retrieved from <https://www.drugs.com/ozempic.html>
[4] National Institute for Health and Care Excellence. (2018). Semaglutide for treating type 2 diabetes. Retrieved from <https://www.nice.org.uk/guidance/ta510>
[5] Wadden, T. A., Hollander, P., Neiberg, R., Knop, F. K., Buse, J. B., Rosenstock, J., ... & Rasmussen, S. B. (2018). Effect of once-weekly semaglutide on body weight and glycaemic control in patients with overweight or obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 391(10134), 1392-1403.